Diagnostic virologic accuracy of CD4 cell count increase for response after initiating highly active antiretroviral therapy

被引:59
作者
Bisson, Gregory P.
Gross, Robert
Strom, Jordan B.
Rollins, Caitlin
Bellamy, Scarlett
Weinstein, Rachel
Friedmand, Harvey
Dickinson, Diana
Frank, Ian
Strom, Brian L.
Gaolathe, Tendani
Ndwapi, Ndwapi
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Med,Div Infect Dis, Philadelphia, PA 19104 USA
[2] Yale Univ, New Haven, CT USA
[3] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[4] Univ Penn, Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA
[5] Princess Marina Hosp, Infect Dis Clin Ctr, Gaborone, Botswana
关键词
HIV-1; HAART; Africa; cohort study; viral load;
D O I
10.1097/01.aids.0000238407.00874.dc
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To derive and internally validate a clinical prediction rule for virologic response based on CD4 cell count increase after initiation of HAART in a resourcelimited setting. Design and methods: A retrospective cohort study at two HIV care clinics in Gaborone, Botswana. The participants were previously treatment-naive HIV-1-infected individuals initiating HAART. The main outcome measure was a plasma HIV-1 RNA level (viral load) <= 400 copies/ml (i.e. undetectable) 6 months after initiating HAART. Results: The ability of CD4 cell count increase to predict an undetectable viral load was significantly better in those with baseline CD4 cell counts <= 100 cells/mu l [area under the ROC curve (AUC), 0.78; 95% confidence interval (CI), 0.67-0.89; versus AUC, 0.60; 95% CI, 0.48-0.71; P=0.018]. The sensitivity, specificity, and positive and negative predictive values of a CD4 cell count increase of >= 50 cells/mu l for an undetectable viral load in those with baseline CD4 cell counts <= 100 cells/mu l were 93.1, 61.3, 92.5 and 63.3%, respectively. Alternatively, these values were 47.8, 87.1, 95.0 and 24.5%, respectively, if a increase in CD4 cell count of >= 150 cells/mu l was used. Conclusions: CD4. cell count increase after initiating HAART has only moderate discriminative ability in identifying patients with an undetectable viral load, and the predictive ability is lower in patients with lower baseline CD4 cell counts. Although HIV treatment programs in resource-constrained settings could consider the use of CD4 cell count increases to triage viral load testing, more accurate approaches to monitoring virologic failure are urgently needed. (c) 2006 Lippincott Williams & Wilkins.
引用
收藏
页码:1613 / 1619
页数:7
相关论文
共 33 条
  • [1] Primary care guidelines for the management of persons infected with human immunodeficiency virus: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America
    Aberg, JA
    Gallant, JE
    Anderson, J
    Oleske, JM
    Libman, H
    Currier, JS
    Stone, VE
    Kaplan, JE
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) : 609 - 629
  • [2] [Anonymous], 2004, SCAL ANT THER RES LT
  • [3] Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy
    Bennett, KK
    DeGruttola, VG
    Marschner, IC
    Havlir, DV
    Richman, DD
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 31 (01) : 20 - 26
  • [4] Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa
    Coetzee, D
    Hildebrand, K
    Boulle, A
    Maartens, G
    Louis, F
    Labatala, V
    Reuter, H
    Ntwana, N
    Goemaere, E
    [J]. AIDS, 2004, 18 (06) : 887 - 895
  • [5] The relationship between virus load response to highly active antiretroviral therapy and change in CD4 cell counts: A report from the women's interagency HIV study
    DeHovitz, JA
    Kovacs, A
    Feldman, JG
    Anastos, K
    Young, M
    Cohen, M
    Gange, SJ
    Melnick, S
    Greenblatt, RM
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05) : 1527 - 1530
  • [7] Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment
    Ferradini, L
    Jeannin, A
    Pinoges, L
    Izopet, J
    Odhiambo, D
    Mankhambo, L
    Karungi, G
    Szumilin, E
    Balandine, S
    Fedida, G
    Carrieri, MP
    Spire, B
    Ford, N
    Tassie, JM
    Guerin, PI
    Brasher, C
    [J]. LANCET, 2006, 367 (9519) : 1335 - 1342
  • [8] Genotypic resistance and immunologic outcomes among HIV-1-infected women with viral failure
    Gange, SJ
    Schneider, MF
    Grant, RM
    Liegler, T
    French, A
    Young, M
    Anastos, K
    Wilson, TE
    Ponath, C
    Greenblatt, R
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 41 (01) : 68 - 74
  • [9] Response to highly active antiretroviral therapy at 6 months and long-term disease progression in HIV-1 infection
    Grabar, S
    Le Moing, V
    Goujard, C
    Egger, M
    Leport, C
    Kazatchkine, MD
    Weiss, L
    Costagliola, D
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (03) : 284 - 292
  • [10] Hamm HE, 1996, FASEB J, V10, P3